Sechenov School
Home › Biochemistry › Orotic Aciduria

Orotic Aciduria

Aciduria orotica

For medical students2 min readUpdated 2026-10-10

Hereditary orotic aciduria is a rare genetic disorder caused by a mutation in the gene encoding the bifunctional enzyme UMP synthase. The condition leads to blocked pyrimidine nucleotide synthesis, massive accumulation of orotic acid, and a severe state known as "pyrimidine starvation".

GeneticsMutation in the gene for the bifunctional enzyme UMP synthase (Type I).
MarkerUrinary excretion of orotate increases up to 1000-fold (up to 1.5 g/day).
SymptomMegaloblastic anemia unresponsive to folates and vitamin B12.
TherapyDaily administration of uridine or cytidine (0.5–1 g/day) as a bypass pathway.

Etiology and Biochemical Defect

The primary cause of hereditary orotic aciduria is a mutation in the gene for the second multifunctional enzyme of pyrimidine synthesis—UMP synthase. Normally, this bifunctional protein sequentially catalyzes two key reactions converting orotic acid into uridine 5'-monophosphate (UMP):

  1. First, the orotate phosphoribosyltransferase activity functions. Orotic acid interacts with phosphoribosyl pyrophosphate (PRPP), resulting in the formation of orotidine 5'-monophosphate (OMP) and the release of pyrophosphate.
  2. Next, the OMP decarboxylase activity functions, which cleaves carbon dioxide from OMP, converting it into the final product—UMP.

In genetic defects of UMP synthase, this pathway is completely blocked. As a result, the conversion of orotate is impaired, and it accumulates in massive amounts in the blood and tissues. Notably, orotic acid itself is not toxic. Nevertheless, its concentration exceeds normal levels to such an extent that urinary excretion reaches 1.5 g/day, which is 1000 times higher than physiological values.

Pathogenesis and Clinical Presentation

The primary cause of all symptoms in orotic aciduria is "pyrimidine starvation". Since UMP is the precursor for all other pyrimidine nucleotides (UTP, CTP, and TTP), blocking its synthesis leaves the body without essential building blocks.

Pyrimidine deficiency impairs the body's ability to maintain normal rates of nucleic acid synthesis (DNA and RNA). This critically affects tissues with high turnover rates:

Thus, clinical manifestations are driven by the arrest of cell division due to the lack of nucleotides, rather than the toxic effects of the accumulating metabolite.

Biochemical Basis of Treatment

Treatment for orotic aciduria is based on utilizing alternative metabolic pathways (salvage pathways). Patients are prescribed uridine or cytidine supplements at a daily dosage of 0.5–1 g.

This replacement therapy addresses two problems simultaneously:

  1. Reversing the deficiency: By the action of uridine kinase (or uridine-cytidine kinase), exogenous uridine is phosphorylated using ATP, directly converting into UMP and bypassing the blocked UMP synthase. The resulting UMP is subsequently converted into UTP and CTP. This immediately resolves "pyrimidine starvation", restores DNA and RNA synthesis, and fully cures megaloblastic anemia.
  2. Eliminating excess orotate: The accumulation of newly formed UTP triggers a feedback inhibition mechanism. Excess UTP allosterically inhibits the key regulatory enzyme of de novo pyrimidine synthesis—carbamoyl phosphate synthetase II (CPS II). As a result, precursor synthesis halts, and the pathological production of orotic acid ceases.

Mnemonic

Uridine Unlocks UMP-deficiency: provide ready-made Uridine, it Ends pyrimidine starvation and Quiets orotic acid synthesis (via CPS II inhibition).

Frequently asked questions

Which enzymes are involved in the de novo biosynthesis of orotic acid prior to the UMP synthase step?

De novo biosynthesis of orotic acid prior to UMP synthase involves the cytosolic CAD enzyme and mitochondrial dihydroorotate dehydrogenase.

The first three reactions are catalyzed by the multifunctional CAD complex, which contains domains with the following activities:

  • Carbamoyl phosphate synthetase II — forms carbamoyl phosphate from glutamine, carbon dioxide, and ATP.
  • Aspartate transcarbamoylase — catalyzes the condensation of carbamoyl phosphate with aspartate to form carbamoylaspartate.
  • Dihydroorotase — promotes dehydration and closure of the pyrimidine ring, forming dihydroorotate.

Next, a separate NAD-dependent enzyme acts:

  • Dihydroorotate dehydrogenase — a mitochondrial enzyme that oxidizes dihydroorotate to orotate (orotic acid).
Why does orotic aciduria cause megaloblastic anemia?

Due to a shortage of pyrimidines, DNA and RNA synthesis is impaired ("pyrimidine starvation"). This inhibits the division of erythroid precursor cells, leading to the formation of large, immature erythrocytes (megaloblasts).

Is orotic acid toxic in high concentrations?

No, orotic acid itself is non-toxic. All clinical manifestations (developmental delay, anemia, cardiac and gastrointestinal disturbances) are exclusively related to pyrimidine nucleotide deficiency.

How does uridine lower urinary orotate levels?

Uridine is converted into UMP and then into UTP. Accumulating UTP exerts negative feedback inhibition on the enzyme carbamoyl phosphate synthetase II (CPS II), halting de novo orotic acid synthesis.

Will vitamin B12 help with anemia caused by orotic aciduria?

No. The megaloblastic anemia in this disorder is specific and unresponsive to standard vitamin B12 or folate therapy because the underlying cause is a genetic block in pyrimidine synthesis.

Go deeper

More topics in Biochemistry

Regulation of Gene Expression in ProkaryotesRegulation of Energy MetabolismRegulation of GlycolysisAtherosclerosis and DyslipidemiasHistidine MetabolismDiabetes MellitusBiotinProtein ChromatographyRegulation of Gene Expression in EukaryotesLactic AcidosisLipid Digestion and AbsorptionBiogenic AminesBiochemistry →